DE602004015406D1 - Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen - Google Patents
Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungenInfo
- Publication number
- DE602004015406D1 DE602004015406D1 DE602004015406T DE602004015406T DE602004015406D1 DE 602004015406 D1 DE602004015406 D1 DE 602004015406D1 DE 602004015406 T DE602004015406 T DE 602004015406T DE 602004015406 T DE602004015406 T DE 602004015406T DE 602004015406 D1 DE602004015406 D1 DE 602004015406D1
- Authority
- DE
- Germany
- Prior art keywords
- alpha
- pregnenolone
- medicament
- methoxy
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0300507A FR2850023B1 (fr) | 2003-01-17 | 2003-01-17 | Medicaments pour le systeme nerveux |
| PCT/FR2004/000086 WO2004067010A1 (fr) | 2003-01-17 | 2004-01-16 | Utilisation de la 3-methoxy-pregnenolone pour la preparation d’un medicament destine a traiter les maladies neurodegeneratives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004015406D1 true DE602004015406D1 (de) | 2008-09-11 |
Family
ID=32605831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004015406T Expired - Lifetime DE602004015406D1 (de) | 2003-01-17 | 2004-01-16 | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8034798B2 (de) |
| EP (1) | EP1583538B1 (de) |
| AT (1) | ATE402710T1 (de) |
| DE (1) | DE602004015406D1 (de) |
| DK (1) | DK1583538T3 (de) |
| ES (1) | ES2311790T3 (de) |
| FR (1) | FR2850023B1 (de) |
| PT (1) | PT1583538E (de) |
| WO (1) | WO2004067010A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| US7981927B2 (en) * | 2007-03-07 | 2011-07-19 | Janssen Pharmaceutica N.V. | Steroids derivatives as selective progesterone receptor modulators |
| AU2012260955B2 (en) * | 2011-05-20 | 2017-08-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antagonists of CB1 receptor. |
| HRP20230747T1 (hr) * | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| ES2621528T3 (es) | 2012-11-28 | 2017-07-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Derivados de 3-(4-sustituido)-bencil éter de pregnenolona |
| CN105246486B (zh) | 2013-03-13 | 2020-11-03 | 萨奇治疗股份有限公司 | 神经活性甾类化合物 |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| EP3319610A4 (de) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | Oxysterole und verfahren zur verwendung davon |
| ES2865258T3 (es) | 2015-07-06 | 2021-10-15 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| KR20240166589A (ko) | 2015-07-06 | 2024-11-26 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| EP3165225A1 (de) | 2015-11-06 | 2017-05-10 | Mapreg | Nicht biologisch umsetzbare c3-substitutierte pregnenolonderivate zur behandlung von drogenmissbrauch |
| WO2017149339A1 (en) | 2016-03-01 | 2017-09-08 | Mapreg | Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression |
| US9943528B2 (en) | 2016-03-01 | 2018-04-17 | Mapreg | Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression |
| MA44526A (fr) | 2016-04-01 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3919502A1 (de) | 2016-07-07 | 2021-12-08 | Sage Therapeutics, Inc. | 11-substituierte 24-hydroxysterole zur verwendung bei der behandlung von nmda-verwandten leiden |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| EP4105223B1 (de) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterole und verfahren zur verwendung davon |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| EP0840612A1 (de) * | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibierung der nmda rezeptoraktivitaet durch pregnolonsulfatderivate |
| US6245757B1 (en) * | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| FR2806303B1 (fr) * | 2000-03-17 | 2002-09-27 | Inst Nat Sante Rech Med | Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| EP1347763A4 (de) * | 2000-11-06 | 2005-10-12 | Univ Boston | Neuraktive steroidderivate und verfahren zu ihrer verwendung |
| EP1310258A1 (de) * | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Steroid-Enantiomere zur Erhöhung des Erinnerungsvermögens und der kognitiven Funktion |
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| US9339508B2 (en) * | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
-
2003
- 2003-01-17 FR FR0300507A patent/FR2850023B1/fr not_active Expired - Lifetime
-
2004
- 2004-01-16 ES ES04702722T patent/ES2311790T3/es not_active Expired - Lifetime
- 2004-01-16 DK DK04702722T patent/DK1583538T3/da active
- 2004-01-16 EP EP04702722A patent/EP1583538B1/de not_active Expired - Lifetime
- 2004-01-16 PT PT04702722T patent/PT1583538E/pt unknown
- 2004-01-16 DE DE602004015406T patent/DE602004015406D1/de not_active Expired - Lifetime
- 2004-01-16 AT AT04702722T patent/ATE402710T1/de active
- 2004-01-16 US US10/542,495 patent/US8034798B2/en not_active Expired - Lifetime
- 2004-01-16 WO PCT/FR2004/000086 patent/WO2004067010A1/fr not_active Ceased
-
2008
- 2008-09-26 US US12/232,993 patent/US8334278B2/en not_active Expired - Lifetime
-
2015
- 2015-11-24 US US14/950,178 patent/US10561671B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1583538B1 (de) | 2008-07-30 |
| PT1583538E (pt) | 2008-10-30 |
| DK1583538T3 (da) | 2008-12-01 |
| FR2850023B1 (fr) | 2007-04-06 |
| EP1583538A1 (de) | 2005-10-12 |
| ATE402710T1 (de) | 2008-08-15 |
| WO2004067010A1 (fr) | 2004-08-12 |
| US20060199790A1 (en) | 2006-09-07 |
| FR2850023A1 (fr) | 2004-07-23 |
| US20090143347A1 (en) | 2009-06-04 |
| US10561671B2 (en) | 2020-02-18 |
| US20160166586A1 (en) | 2016-06-16 |
| US8034798B2 (en) | 2011-10-11 |
| ES2311790T3 (es) | 2009-02-16 |
| US8334278B2 (en) | 2012-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004015406D1 (de) | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen | |
| ATE268179T1 (de) | Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung | |
| UA85708C2 (ru) | Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей | |
| IL171977A (en) | Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| ATE369353T1 (de) | Medizinisch verwendbare arylethanolamin verbindungen | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| ATE485258T1 (de) | Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase | |
| SE0104340D0 (sv) | New compounds | |
| NO20070576L (no) | Nye hydantionderivater for behandling av obstruktive luftveissykdommer. | |
| BRPI0412999A (pt) | 2-aminotetralina substituìda para tratamento de depressão | |
| DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
| WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| DE502005008058D1 (de) | Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen | |
| DE602005023782D1 (de) | Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| ATE340579T1 (de) | Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung | |
| BRPI0407968A (pt) | derivados de oxamida úteis como inibidores de raf-quinase | |
| TW200604196A (en) | New quinuclidine derivatives and pharmaceutical compositions comprising them | |
| AR040441A1 (es) | Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| ATE339202T1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
| DE60041137D1 (de) | Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |